MedWatch

Olympus divests optics division for USD 3bn

Rumors of a transaction between Olympus and US-based private equity firm Bain are now confirmed by the Japanese pharmaceutical giant, which secures JPY 427.7bn (USD 3.08bn) from divesting its scientific optics division.

Photo: YURIKO NAKAO/REUTERS / X90018

Japanese pharmaceutical company Olympus is selling its scientific optics division to US private equity firm Bain for more than JPY 427bn (USD 3bn), the former confirms as cited by Bloomberg News following last weeks rumors of such a divestment.

The sale is meant to raise growth and profitability for the Japanese company, which is reportedly seeking to sharpen its focus on pharma.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs